FindTrial
Sign In

STI-3031

BIOLOGICAL2 trials

Sponsors

Sorrento Therapeutics, Inc.

Conditions

Biliary Tract CancerDiffuse Large B Cell LymphomaExtranodal NK T Cell Lymphoma, NasalPeripheral T Cell LymphomaRefractory TumorRelapsed Solid TumorSolid Tumor

Phase 2

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
WithdrawnNCT03999658
Sorrento Therapeutics, Inc.Biliary Tract Cancer, Diffuse Large B Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal +1
Start: 2023-03-31End: 2024-07-31Updated: 2023-05-01
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
WithdrawnNCT04809012
Sorrento Therapeutics, Inc.Refractory Tumor, Relapsed Solid Tumor, Solid Tumor
Start: 2021-06-30End: 2024-06-30Updated: 2022-03-25